First Patient in Neurizon's NUZ-001 ALS Trial Enters Active Treatment Extension

• Neurizon Therapeutics announced November 13, 2026, that the first participant in its NUZ-001 ALS trial entered the active treatment extension.
• The optional extension provides NUZ-001 following 36 weeks of placebo-controlled treatment, gathering longer-term safety data rather than separately assessing efficacy.
• Regimen I of the Phase 2/3 HEALEY ALS Platform Trial completed enrollment in July 2026 with 250 participants across 78 US sites.
• Topline results from the randomized controlled phase are expected in late second-quarter 2027.
• FDA feedback indicated Regimen I could support a traditional approval application as a single registrational study, subject to results and confirmatory evidence.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.